☰

Joseph F. Grosso, Ph.D. - Publications

Affiliations: 
2004 University of Miami, Coral Gables, FL 
Area:
Immunology, Microbiology Biology
Tree Info Similar researchers PubMed Report error

41 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Drilon A, Wolchok JD, Carvajal RD, ... ... Grosso JF, et al. Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non-Small Cell Lung Cancer Treated With Nivolumab. Jama Oncology. PMID 31343665 DOI: 10.1001/Jamaoncol.2019.2187  0.324
2017 Lewis KE, Selby MJ, Masters G, Valle J, Dito G, Curtis WR, Garcia R, Mink KA, Waggie KS, Holdren MS, Grosso JF, Korman AJ, Jure-Kunkel M, Dillon SR. Interleukin-21 combined with PD-1 or CTLA-4 blockade enhances antitumor immunity in mouse tumor models. Oncoimmunology. 7: e1377873. PMID 29296539 DOI: 10.1080/2162402X.2017.1377873  0.521
2017 Majzner RG, Simon JS, Grosso JF, Martinez D, Pawel BR, Santi M, Merchant MS, Geoerger B, Hezam I, Marty V, Vielh P, Daugaard M, Sorensen PH, Mackall CL, Maris JM. Assessment of programmed death-ligand 1 expression and tumor-associated immune cells in pediatric cancer tissues. Cancer. PMID 28608950 DOI: 10.1002/Cncr.30724  0.472
2016 Lesokhin AM, Ansell SM, Armand P, Scott EC, Halwani A, Gutierrez M, Millenson MM, Cohen AD, Schuster SJ, Lebovic D, Dhodapkar M, Avigan D, Chapuy B, Ligon AH, Freeman GJ, ... ... Grosso JF, et al. Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 27269947 DOI: 10.1200/Jco.2015.65.9789  0.446
2015 Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, Schuster SJ, Millenson MM, Cattry D, Freeman GJ, Rodig SJ, Chapuy B, Ligon AH, Zhu L, Grosso JF, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. The New England Journal of Medicine. 372: 311-9. PMID 25482239 DOI: 10.1056/Nejmoa1411087  0.385
2015 Antonia SJ, Bendell JC, Taylor MH, Calvo E, Jaeger D, De Braud FG, Ott PA, Pietanza MC, Horn L, Le DT, Morse M, Lopez-Martin JA, Ascierto PA, Christensen O, Grosso J, et al. Phase I/II study of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC): CA209-032. Journal of Clinical Oncology. 33: 7503-7503. DOI: 10.1200/Jco.2015.33.15_Suppl.7503  0.389
2015 Sampson JH, Vlahovic G, Sahebjam S, Omuro AMP, Baehring JM, Hafler DA, Voloschin AD, Paliwal P, Grosso J, Coric V, Cloughesy TF, Lim M, Reardon DA. Preliminary safety and activity of nivolumab and its combination with ipilimumab in recurrent glioblastoma (GBM): CHECKMATE-143. Journal of Clinical Oncology. 33: 3010-3010. DOI: 10.1200/Jco.2015.33.15_Suppl.3010  0.389
2015 Majzner RG, Simon JS, Grosso JF, Martinez D, Pawel B, Santi-Vincini M, Merchant MS, Sorensen P, Mackall CL, Maris JM. Abstract 249: Assessment of PD-L1 expression and tumor-associated lymphocytes in pediatric cancer tissues Cancer Research. 75: 249-249. DOI: 10.1158/1538-7445.Am2015-249  0.452
2015 Antonia S, Bendell J, Taylor M, Calvo E, Jäger D, de Braud F, Ott P, Pietanza M, Horn L, Le D, Morse M, López-Martin J, Ascierto P, Christensen O, Grosso J, et al. Phase 1/2 study of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC): CA209-032 Annals of Oncology. 26: vi74. DOI: 10.1093/Annonc/Mdv343.05  0.301
2014 Postow MA, Cardona DM, Taube JM, Anders RA, Taylor CR, Wolchok JD, Callahan MK, Curran MA, Lesokhin AM, Grosso JF, Horak CE, Cogswell J, Simon JS, Gupta AK, Sznol M. Peripheral and tumor immune correlates in patients with advanced melanoma treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) monotherapy or in combination with ipilimumab Journal of Translational Medicine. 12: O8. DOI: 10.1186/1479-5876-12-S1-O8  0.409
2014 Lesokhin AM, Ansell SM, Armand P, Scott EC, Halwani A, Gutierrez M, Millenson MM, Cohen AD, Schuster SJ, Lebovic D, Dhodapkar MV, Avigan D, Chapuy B, Ligon AH, Rodig SJ, ... ... Grosso JF, et al. Preliminary Results of a Phase I Study of Nivolumab (BMS-936558) in Patients with Relapsed or Refractory Lymphoid Malignancies Blood. 124: 291-291. DOI: 10.1182/Blood.V124.21.291.291  0.479
2014 Armand P, Ansell SM, Lesokhin AM, Halwani A, Millenson MM, Schuster SJ, Timmerman J, Borrello I, Gutierrez M, Scott EC, Cattry D, Chapuy B, Ligon AH, Rodig SJ, Zhu L, ... Grosso JF, et al. Nivolumab in Patients with Relapsed or Refractory Hodgkin Lymphoma - Preliminary Safety, Efficacy and Biomarker Results of a Phase I Study Blood. 124: 289-289. DOI: 10.1182/Blood.V124.21.289.289  0.465
2013 Wada S, Jackson CM, Yoshimura K, Yen HR, Getnet D, Harris TJ, Goldberg MV, Bruno TC, Grosso JF, Durham N, Netto GJ, Pardoll DM, Drake CG. Sequencing CTLA-4 blockade with cell-based immunotherapy for prostate cancer. Journal of Translational Medicine. 11: 89. PMID 23557194 DOI: 10.1186/1479-5876-11-89  0.32
2013 Grosso JF, Jure-Kunkel MN. CTLA-4 blockade in tumor models: an overview of preclinical and translational research. Cancer Immunity. 13: 5. PMID 23390376  0.428
2013 Chow LQM, Gordon MS, Logan TF, Antonia SJ, Bhatia S, Thompson JA, Brahmer JR, Solberg G, Bittner R, Fontana D, Grosso J, Cohen LJ, Ahlers CM, Wigginton JM, Drake CG. Phase I dose escalation study of recombinant interleukin-21 (rIL-21; BMS-982470) in combination with nivolumab (anti-PD-1; BMS-936558; ONO-4538) in patients (pts) with advanced or metastatic solid tumors. Journal of Clinical Oncology. 31: TPS3112-TPS3112. DOI: 10.1200/Jco.2013.31.15_Suppl.Tps3112  0.489
2013 Bhatia S, Curti BD, Gordon MS, Chesney J, Logan T, Thompson JA, Royer N, Bittner R, Fontana D, Grosso J, Clemens PL, Cohen LJ, Ahlers CM, Wigginton JM, Hwu P. Phase I dose escalation study of recombinant interleukin-21 (rIL-21, BMS-982470) in combination with ipilimumab (Ipi) in patients (pts) with advanced or metastatic melanoma (MM). Journal of Clinical Oncology. 31: TPS3109-TPS3109. DOI: 10.1200/Jco.2013.31.15_Suppl.Tps3109  0.421
2013 Jure-Kunkel M, Selby M, Lewis K, Masters G, Valle J, Grosso J, Dito G, Curtis W, Garcia R, Holdren M, Korman AJ, Dillon S. Nonclinical evaluation of the combination of mouse IL-21 and anti- mouse CTLA-4 or PD-1 blocking antibodies in mouse tumor models. Journal of Clinical Oncology. 31: 3019-3019. DOI: 10.1200/Jco.2013.31.15_Suppl.3019  0.521
2013 Grosso J, Horak CE, Inzunza D, Cardona DM, Simon JS, Gupta AK, Sankar V, Park J, Kollia G, Taube JM, Anders R, Jure-Kunkel M, Novotny J, Taylor CR, Zhang X, et al. Association of tumor PD-L1 expression and immune biomarkers with clinical activity in patients (pts) with advanced solid tumors treated with nivolumab (anti-PD-1; BMS-936558; ONO-4538). Journal of Clinical Oncology. 31: 3016-3016. DOI: 10.1200/Jco.2013.31.15_Suppl.3016  0.448
2013 Callahan MK, Horak CE, Curran MA, Hollman T, Schaer DA, Yuan J, Lesokhin AM, Kitano S, Hong Q, Ariyan CE, Busam KJ, Feely W, Jure-Kunkel M, Grosso J, Simon JS, et al. Peripheral and tumor immune correlates in patients with advanced melanoma treated with combination nivolumab (anti-PD-1, BMS-936558, ONO-4538) and ipilimumab. Journal of Clinical Oncology. 31: 3003-3003. DOI: 10.1200/Jco.2013.31.15_Suppl.3003  0.519
2013 Grosso J, Inzunza D, Wu Q, Simon J, Singh P, Zhang X, Phillips T, Simmons P, Cogswell J. Programmed death-ligand 1 (PD-L1) expression in various tumor types Journal For Immunotherapy of Cancer. 1. DOI: 10.1186/2051-1426-1-S1-P53  0.46
2013 Callahan MK, Horak CE, Curran MA, Hollman T, Schaer DA, Yuan J, Lesokhin AM, Kitano S, Hong Q, Ariyan CE, Busam KJ, Feely W, Jure-Kunkel M, Grosso J, Simon JS, et al. Peripheral blood and tumor biomarkers in patients with advanced melanoma treated with combination nivolumab (anti-PD-1, BMS-936558, ONO-4538) and ipilimumab Journal For Immunotherapy of Cancer. 1. DOI: 10.1186/2051-1426-1-S1-O6  0.524
2012 Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, Pitot HC, Hamid O, Bhatia S, Martins R, Eaton K, ... ... Grosso JF, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. The New England Journal of Medicine. 366: 2455-65. PMID 22658128 DOI: 10.1056/Nejmoa1200694  0.435
2012 Woo SR, Turnis ME, Goldberg MV, Bankoti J, Selby M, Nirschl CJ, Bettini ML, Gravano DM, Vogel P, Liu CL, Tangsombatvisit S, Grosso JF, Netto G, Smeltzer MP, Chaux A, et al. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Research. 72: 917-27. PMID 22186141 DOI: 10.1158/0008-5472.Can-11-1620  0.544
2012 Bruno TC, Rothwell C, Grosso JF, Getnet D, Yen HR, Durham NM, Netto G, Pardoll DM, Drake CG. Anti-tumor effects of endogenous prostate cancer-specific CD8 T cells in a murine TCR transgenic model. The Prostate. 72: 514-22. PMID 21761425 DOI: 10.1002/Pros.21453  0.521
2011 Goldberg MV, Woo S, Bankoti J, Selby M, Nirschl CJ, Bettini ML, Vogel P, Grosso JF, Netto G, Chaux A, Smeltzer M, Workman CJ, Pardoll DM, Korman AJ, Vignali DA, et al. Abstract LB-251: The checkpoint molecules LAG-3 and PD-1 synergize to maintain tolerance to tumors Cancer Research. 71. DOI: 10.1158/1538-7445.Am2011-Lb-251  0.544
2010 Getnet D, Grosso JF, Goldberg MV, Harris TJ, Yen HR, Bruno TC, Durham NM, Hipkiss EL, Pyle KJ, Wada S, Pan F, Pardoll DM, Drake CG. A role for the transcription factor Helios in human CD4(+)CD25(+) regulatory T cells. Molecular Immunology. 47: 1595-600. PMID 20226531 DOI: 10.1016/J.Molimm.2010.02.001  0.403
2009 Yen HR, Harris TJ, Wada S, Grosso JF, Getnet D, Goldberg MV, Liang KL, Bruno TC, Pyle KJ, Chan SL, Anders RA, Trimble CL, Adler AJ, Lin TY, Pardoll DM, et al. Tc17 CD8 T cells: functional plasticity and subset diversity. Journal of Immunology (Baltimore, Md. : 1950). 183: 7161-8. PMID 19917680 DOI: 10.4049/Jimmunol.0900368  0.398
2009 Pan F, Yu H, Dang EV, Barbi J, Pan X, Grosso JF, Jinasena D, Sharma SM, McCadden EM, Getnet D, Drake CG, Liu JO, Ostrowski MC, Pardoll DM. Eos mediates Foxp3-dependent gene silencing in CD4+ regulatory T cells. Science (New York, N.Y.). 325: 1142-6. PMID 19696312 DOI: 10.1126/Science.1176077  0.373
2009 Grosso JF, Goldberg MV, Getnet D, Bruno TC, Yen HR, Pyle KJ, Hipkiss E, Vignali DA, Pardoll DM, Drake CG. Functionally distinct LAG-3 and PD-1 subsets on activated and chronically stimulated CD8 T cells. Journal of Immunology (Baltimore, Md. : 1950). 182: 6659-69. PMID 19454660 DOI: 10.4049/Jimmunol.0804211  0.467
2009 Wada S, Yoshimura K, Hipkiss EL, Harris TJ, Yen HR, Goldberg MV, Grosso JF, Getnet D, Demarzo AM, Netto GJ, Anders R, Pardoll DM, Drake CG. Cyclophosphamide augments antitumor immunity: studies in an autochthonous prostate cancer model. Cancer Research. 69: 4309-18. PMID 19435909 DOI: 10.1158/0008-5472.Can-08-4102  0.48
2009 Getnet D, Maris CH, Hipkiss EL, Grosso JF, Harris TJ, Yen HR, Bruno TC, Wada S, Adler A, Georgantas RW, Jie C, Goldberg MV, Pardoll DM, Drake CG. Tumor recognition and self-recognition induce distinct transcriptional profiles in antigen-specific CD4 T cells. Journal of Immunology (Baltimore, Md. : 1950). 182: 4675-85. PMID 19342643 DOI: 10.4049/Jimmunol.0803400  0.533
2008 Harris TJ, Hipkiss EL, Borzillary S, Wada S, Grosso JF, Yen HR, Getnet D, Bruno TC, Goldberg MV, Pardoll DM, DeWeese TL, Drake CG. Radiotherapy augments the immune response to prostate cancer in a time-dependent manner. The Prostate. 68: 1319-29. PMID 18561247 DOI: 10.1002/Pros.20794  0.465
2007 Grosso JF, Drake CG. Current immunotherapeutic strategies in prostate cancer. Surgical Oncology Clinics of North America. 16: 861-71, x. PMID 18022549 DOI: 10.1016/J.Soc.2007.07.009  0.314
2007 Grosso JF, Kelleher CC, Harris TJ, Maris CH, Hipkiss EL, De Marzo A, Anders R, Netto G, Getnet D, Bruno TC, Goldberg MV, Pardoll DM, Drake CG. LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems. The Journal of Clinical Investigation. 117: 3383-92. PMID 17932562 DOI: 10.1172/Jci31184  0.51
2007 Harris TJ, Grosso JF, Yen HR, Xin H, Kortylewski M, Albesiano E, Hipkiss EL, Getnet D, Goldberg MV, Maris CH, Housseau F, Yu H, Pardoll DM, Drake CG. Cutting edge: An in vivo requirement for STAT3 signaling in TH17 development and TH17-dependent autoimmunity. Journal of Immunology (Baltimore, Md. : 1950). 179: 4313-7. PMID 17878325 DOI: 10.4049/Jimmunol.179.7.4313  0.404
2007 Goldberg MV, Maris CH, Hipkiss EL, Flies AS, Zhen L, Tuder RM, Grosso JF, Harris TJ, Getnet D, Whartenby KA, Brockstedt DG, Dubensky TW, Chen L, Pardoll DM, Drake CG. Role of PD-1 and its ligand, B7-H1, in early fate decisions of CD8 T cells. Blood. 110: 186-92. PMID 17392506 DOI: 10.1182/Blood-2006-12-062422  0.466
2006 Drake CG, Kelleher C, Bruno T, Harris T, Flies D, Getnet D, Hipkiss E, Maris C, Grosso J. Blocking the regulatory T cell molecule LAG-3 augments in vivo anti-tumor immunity in an autochthonous model of prostate cancer Journal of Clinical Oncology. 24: 2573-2573. DOI: 10.1200/Jco.2006.24.18_Suppl.2573  0.573
2005 Owen JL, Lopez DM, Grosso JF, Guthrie KM, Herbert LM, Torroella-Kouri M, Iragavarapu-Charyulu V. The expression of CCL2 by T lymphocytes of mammary tumor bearers: role of tumor-derived factors. Cellular Immunology. 235: 122-35. PMID 16243300 DOI: 10.1016/J.Cellimm.2005.08.032  0.714
2004 Herbert LM, Grosso JF, Dorsey M, Fu T, Keydar I, Cejas MA, Wreschner DH, Smorodinski N, Lopez DM. A unique mucin immunoenhancing peptide with antitumor properties. Cancer Research. 64: 8077-84. PMID 15520219 DOI: 10.1158/0008-5472.Can-04-0853  0.616
2004 Grosso JF, Herbert LM, Owen JL, Lopez DM. MUC1/sec-expressing tumors are rejected in vivo by a T cell-dependent mechanism and secrete high levels of CCL2. Journal of Immunology (Baltimore, Md. : 1950). 173: 1721-30. PMID 15265901 DOI: 10.4049/Jimmunol.173.3.1721  0.703
2003 Owen JL, Iragavarapu-Charyulu V, Gunja-Smith Z, Herbert LM, Grosso JF, Lopez DM. Up-regulation of matrix metalloproteinase-9 in T lymphocytes of mammary tumor bearers: role of vascular endothelial growth factor. Journal of Immunology (Baltimore, Md. : 1950). 171: 4340-51. PMID 14530359 DOI: 10.4049/Jimmunol.171.8.4340  0.691
Show low-probability matches.